A young girl, infant 4 months old and young man showing a broad spectrum of young people
Bexsero: Help protect against a broad population¹

Bexsero is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.1

family-baby

Meningitis B awareness: Did you know?

2 of 3 parents are unaware that there is a separate vaccine against meningitis B.

Some parents believe that their child may have already been protected from meningitis B with just a meningococcal conjugate (MenACWY) vaccine.4,a

ᵃN=3600 parents and legal guardians from 8 countries (Australia, Brazil, Germany, Greece, Italy, Spain, UK, and USA) participated in a survey.

Common questions and answers with Bexsero

When your patients and their parents come to you with these common questions, Bexsero may be the answer.

References:

  1. Bexsero Summary of Product Characteristics. GSK Vaccines S.r.l; 2020.
  2. Deceuninck G, Lefebvre B, Tsang R, Betala-Belinga JF, De Serres G, De Wals P. Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch. Vaccine. 2019;37(31):4243–4245.
  3. Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309–317.
  4. GSK Data on file: 2017N320400_05.
  5. European Center for Disease Prevention and Control. Surveillance atlas of infectious diseases. http://atlas.ecdc.europa.eu/public/index.aspx. Accessed April 2020.
  6. Pfizer Ltd. Trumenba  Annex I; Summary of Product Characteristics EMA; June 2020.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

L.K January 2021 PM-GB-BEX-WCNT-200001